Since studies have shown that the COX-2 inhibitor, celecoxib, inhibited this metastatic process [84], these findings may explain why the celecoxib-combined neoadjuvant therapy is beneficial for breast cancer patients. Here, PTGS2 is linked to breast carcinoma.